2010
Racial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3
Fowke JH, Matthews CE, Yu H, Cai Q, Cohen S, Buchowski MS, Zheng W, Blot WJ. Racial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3. Endocrine Related Cancer 2010, 17: 51-60. PMID: 19786462, PMCID: PMC2814999, DOI: 10.1677/erc-09-0023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge of OnsetAgedBlack or African AmericanBody Mass IndexBreast NeoplasmsCross-Sectional StudiesFemaleFollow-Up StudiesGenetic Predisposition to DiseaseHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Binding ProteinsInsulin-Like Growth Factor IInsulin-Like Growth Factor IIMiddle AgedPostmenopausePremenopauseProspective StudiesSoutheastern United StatesWhite PeopleYoung AdultConceptsBody mass indexAge 21 yearsBreast cancer riskIGF1 levelsRace/ethnicityIGFBP3 levelsMass indexWhite womenAA womenCancer riskRacial differencesPremenopausal breast cancer riskAfrican American race/ethnicityLower body mass indexEffect of obesityHigher IGF1 levelsCross-sectional analysisFree IGF1Serum IGF1IGF levelsBMI rangeAge 40Wide BMI rangeProtein 3Women
2006
Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer
Wolfort R, de Benedetti A, Nuthalapaty S, Yu H, Chu Q, Li B. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer. Surgery 2006, 140: 161-169. PMID: 16904965, DOI: 10.1016/j.surg.2006.05.001.Peer-Reviewed Original Research
2005
A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Positive Breast Cancer
McClusky D, Chu Q, Yu H, DeBenedetti A, Johnson L, Meschonat C, Turnage R, McDonald J, Abreo F, Li B. A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Positive Breast Cancer. Annals Of Surgery 2005, 123: 278-286. PMID: 16192819, PMCID: PMC1402342, DOI: 10.1097/01.sla.0000184224.55949.90.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBlotting, WesternBreast NeoplasmsElectrophoresis, Polyacrylamide GelEukaryotic Initiation Factor-4EFemaleFollow-Up StudiesHumansIncidenceLymph NodesLymphatic MetastasisMastectomy, Extended RadicalMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingProspective StudiesRisk FactorsSurvival RateConceptsNode-positive breast cancerBreast cancerCancer recurrenceHighest tertileEIF4E overexpressionProspective trialNodal statusHigher cancer recurrence rateCancer-related death rateCox proportional hazards modelNode-positive diseaseKaplan-Meier methodCancer recurrence rateLog-rank testCancer-related deathProportional hazards modelRelative risk increaseHigh eIF4E overexpressionRelative risk calculationsMedian followDisease recurrenceIndependent predictorsIntermediate tertileNoncancer patientsProspective study
2001
IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival
Katsaros D, Yu H, Levesque M, Danese S, Genta F, Richiardi G, Fracchioli S, Khosravi M, Diamandi A, Gordini G, Diamandis E, Massobrio M. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. European Journal Of Cancer 2001, 37: 478-485. PMID: 11267857, DOI: 10.1016/s0959-8049(00)00423-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesHumansInsulin-Like Growth Factor Binding Protein 3Middle AgedNeoplasm ProteinsNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisRisk FactorsConceptsIGFBP-3 levelsInsulin-like growth factorLower IGFBP-3 levelsEpithelial ovarian carcinomaIGFBP-3Overall survivalPatient survivalOvarian carcinomaGrowth factorUnfavourable prognostic featuresIGFBP-3 concentrationsClinico-pathological featuresEpithelial ovarian cancerPatients' overall survivalResponse of patientsOvarian cancer progressionAnti-apoptotic actionClinicopathological featuresPathological variablesPrognostic featuresResidual tumorDisease progressionOvarian cancerDisease prognosisAverage age
2000
Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up
Vassilikos E, Yu H, Trachtenberg J, Nam R, Narod S, Bromberg I, Diamandis E. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clinical Biochemistry 2000, 33: 115-123. PMID: 10751589, DOI: 10.1016/s0009-9120(99)00099-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedDisease-Free SurvivalFluorescent Antibody TechniqueFollow-Up StudiesHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingProportional Hazards ModelsProstate-Specific AntigenProstatectomyProstatic NeoplasmsRecurrenceRegression AnalysisReproducibility of ResultsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsProstate cancer patientsRadical prostatectomySerum PSACancer patientsPSA assaysUltrasensitive prostate specific antigenPre-operative PSAGroup of patientsSerial serum samplesEarly therapeutic interventionSeminal vesicle invasionSurgical margin positivityProstate-specific antigenRegular PSAUltrasensitive PSAPSA increaseMargin positivityClinical stageGleason scorePrognostic indicatorCapsular invasionTissue involvementTumor volumePatientsFast relapse
1999
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination
Yu H, Levesque M, Clark G, Diamandis E. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. British Journal Of Cancer 1999, 81: 490-495. PMID: 10507775, PMCID: PMC2362935, DOI: 10.1038/sj.bjc.6690720.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBiomarkers, TumorBreast NeoplasmsCarcinomaChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDNA ReplicationEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGenes, p53HumansLife TablesLymphatic MetastasisMastectomyMultivariate AnalysisNeoplasm ProteinsNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentPloidiesPrognosisProportional Hazards ModelsProstate-Specific AntigenRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneRiskSensitivity and SpecificitySurvival AnalysisSurvival RateTreatment OutcomeTumor Suppressor Protein p53ConceptsEnzyme-linked immunosorbent assayDisease-free survivalBreast cancer patientsCancer patientsRelative riskCox proportional hazards regression analysisProstate-specific antigen expressionProportional hazards regression analysisReceipt of chemotherapyProgesterone receptor statusSteroid hormone receptor analysisHazards regression analysisRecent clinical evidenceLog-rank testKaplan-Meier plotsOverall survival probabilityHormone receptor analysisPrimary breast carcinomaQuantitative enzyme-linked immunosorbent assayProstate-specific antigenP53 expression statusAssessment of p53Breast cancer prognosisS-phase fractionExpression of p53Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
Foekens J, Diamandis E, Yu H, Look M, Gelder M, Putten W, Klijn J. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. British Journal Of Cancer 1999, 79: 888-894. PMID: 10070886, PMCID: PMC2362687, DOI: 10.1038/sj.bjc.6690142.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, HormonalBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphatic MetastasisMiddle AgedNeoplasm StagingPostmenopausePredictive Value of TestsPremenopauseProstate-Specific AntigenReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesSurvival AnalysisTamoxifenTime FactorsConceptsLevels of PSAProstate-specific antigenPrimary breast cancerRecurrent breast cancerBreast tumor cytosolsBreast cancerRecurrent diseaseEnzyme-linked immunosorbent assayTamoxifen therapyPoor responseTumor cytosolsAge/menopausal statusFirst-line tamoxifen therapyHormone receptor-negative tumorsSteroid hormone receptor statusDisease-free intervalSite of relapseCox multivariate analysisHormone receptor statusReceptor-negative tumorsClassical prognostic factorsPost-menopausal patientsRate of relapseBreast cancer patientsStart of treatment
1998
Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
Yu H, Levesque M, Clark G, Diamandis E. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clinical Cancer Research 1998, 4: 1489-97. PMID: 9626467.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceBiomarkers, TumorBreast NeoplasmsCohort StudiesCytosolFemaleFollow-Up StudiesHumansLymphatic MetastasisMiddle AgedPloidiesPrognosisProstate-Specific AntigenReceptors, EstrogenReceptors, ProgesteroneS PhaseSurvival AnalysisTime FactorsUnited StatesConceptsProstate-specific antigenPrimary breast cancerBreast cancerCohort studyPrognostic valueRelative riskBreast tumorsSteroid hormone receptor levelsLow S-phase fractionMeasurement of PSAPSA-negative patientsPSA-positive patientsPrognosis of patientsYounger patient ageHormone receptor levelsLarge cohort studyUnited States cohort studyValuable tumor markerS-phase fractionUnited States patientsBreast tumor extractsMedian followPSA presenceNodal statusPatient age
1997
Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l
Yu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918. PMID: 9072598, DOI: 10.1016/s0022-5347(01)65082-1.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPositive surgical marginsPreoperative prostate-specific antigenSerum prostate-specific antigenSerial serum samplesBiochemical relapseSurgical marginsClinicopathological featuresRadical prostatectomyTumor volumeLogistic regression modelsPSA changeGreater preoperative prostate specific antigenPostoperative serum prostate-specific antigenHigher preoperative prostate-specific antigenPostoperative prostate-specific antigenUnconditional logistic regression modelsSerum samplesProstate-specific antigen monitoringSerum PSA changesSubset of patientsUnivariate logistic regression modelYear of surgeryLength of followupConventional prostate specific antigen